

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the application:

1-20. (Cancelled)

21. (Currently amended) A composition for regenerating nerves, comprising an agent capable of inhibiting a p75 signal transduction pathway, wherein the agent ~~comprises a transduction agent in the p75 signal transduction pathway or a variant or fragment thereof, or an agent capable of specifically interacting with the transduction agent in the p75 signal transduction pathway; and is a~~ Pep5 polypeptide having the sequence of SEQ ID NO:2, or a sequence derived therefrom by one or several amino acid substitutions, deletions, and additions which retains the biological activity of Pep5; and  
wherein the agent ~~is bound to~~ comprises a PTD domain.

22. (Original) A composition according to claim 21, wherein the agent capable of inhibiting the p75 signal transduction pathway is in a form appropriate for delivery to a neuron at a site desired for nerve regeneration.

23. (Canceled)

24. (Withdrawn) A composition according to claim 23, wherein the transduction agent in the p75 signal transduction pathway comprises at least one transduction agent selected from the group consisting of MAG, PKC, IP<sub>3</sub>, GT1b, p75, Rho GDI, Rho, p21, and Rho kinase.

25. (Currently amended) A composition according to claim 21, wherein the agent capable of inhibiting the p75 signal transduction pathway ~~has at least one~~ the

~~action selected from the group consisting of inhibition of an interaction between p75 and Rho, inhibition of an interaction between p75 and Rho GDI, maintenance or enhancement of an interaction between Rho and Rho GDI, inhibition of conversion from Rho-GDP to Rho-GTP, inhibition of an interaction between Rho and Rho-kinase, and inhibition of an activity of Rho-kinase.~~

26. (Currently amended) A composition according to claim 21, wherein the agent capable of inhibiting the p75 signal transduction pathway comprises at least ~~one agent selected from the group consisting of an agent capable of suppressing or extinguishing an interaction between p75 and Rho GDI, an agent capable of suppressing or extinguishing an interaction between p75 and Rho, an agent capable of maintaining or enhancing an interaction between Rho and Rho GDI, an agent capable of inhibiting conversion from Rho-GDP to Rho-GTP, an agent capable of inhibiting an interaction between Rho and Rho-kinase, and an agent capable of inhibiting an activity of Rho-kinase, and wherein~~

the agent capable of inhibiting the p75 signal transduction pathway is present in an amount effective for regeneration.

27. (Currently amended) A composition for regenerating nerves comprising an agent capable of inhibiting a p75 signal transduction pathway, wherein the agent is a Pep5 polypeptide having the sequence of SEQ ID NO:2, or a sequence derived therefrom by one or several amino acid substitutions, deletions, and additions which retains the biological activity of Pep5; ~~comprises a transduction agent in the p75 signal transduction pathway or a variant or fragment thereof, or an agent capable of specifically interacting with the transduction agent in the p75 signal transduction pathway,~~

wherein the agent comprises a PTD domain; and

wherein the composition is suitable for *in vivo* or *in vitro* administration forms.

28. (Currently amended) A composition according to claim ~~24~~22, wherein the nerve regeneration is selected from the group consisting of ~~includes~~ spinal cord injury, cerebrovascular disorder, ~~or~~and brain injury.

29-262. (Cancelled)

263. (New) A kit for regenerating nerves, comprising:

- (a) a container comprising a composition according to claim 21 or 27, and
- (b) instructions for using the composition of (a).

264. (New) A medicament for regenerating nerves comprising the composition of claim 21 or 27.

265. (New) The medicament of claim 264, wherein said medicament is a solid formulation selected from the group consisting of a tablet, pill, capsule, granule, abstract, powder, and suppository.

266. (New) The medicament of claim 265, wherein said medicament is a liquid formulation selected from the group consisting of a syrup, an injection, a suspension, a solution, and a spray agent.